About Immatics
Immatics is a company based in Tubingen (Germany) founded in 2000.. Immatics has raised $236.4 million across 9 funding rounds from investors including 3i Group, European Union and KfW. The company has 423 employees as of December 31, 2024. Immatics offers products and services including Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT. Immatics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Tubingen, Germany
- Employees 423 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Immatics N.V.
-
Annual Revenue
$168.57 M188.75as on Dec 31, 2024
-
Net Profit
$16.46 M116.09as on Dec 31, 2024
-
EBITDA
$-28.63 M72.31as on Dec 31, 2024
-
Total Equity Funding
$236.4 M (USD)
in 9 rounds
-
Latest Funding Round
$35 M (USD), Post-IPO
Jul 24, 2023
-
Investors
3i Group
& 15 more
-
Employee Count
423
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Immatics
Immatics is a publicly listed company on the NASDAQ with ticker symbol IMTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Immatics
Immatics offers a comprehensive portfolio of products and services, including Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
T cell-based treatments targeting solid tumors in clinical trials.
Bispecific antibodies for enhancing T cell responses against cancer.
Innovative cell therapies for improved cancer treatment efficacy.
Unlock access to complete
Unlock access to complete
Funding Insights of Immatics
Immatics has successfully raised a total of $236.4M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Post-IPO — $35.0M
-
First Round
First Round
(01 Mar 2004)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2023 | Amount | Post-IPO - Immatics | Valuation |
investors |
|
| Aug, 2020 | Amount | Post-IPO - Immatics | Valuation |
investors |
|
| Oct, 2017 | Amount | Series E - Immatics | Valuation | Dievini , Amgen Business Development |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Immatics
Immatics has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include 3i Group, European Union and KfW. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity investments are managed.
|
Founded Year | Domain | Location | |
|
Investments are made in early-stage healthcare startups.
|
Founded Year | Domain | Location | |
|
Investments are made in life and health sciences companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Immatics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Immatics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immatics Comparisons
Competitors of Immatics
Immatics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Immatics
Frequently Asked Questions about Immatics
When was Immatics founded?
Immatics was founded in 2000 and raised its 1st funding round 4 years after it was founded.
Where is Immatics located?
Immatics is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.
Is Immatics a funded company?
Immatics is a funded company, having raised a total of $236.4M across 9 funding rounds to date. The company's 1st funding round was a Series E of $58M, raised on Mar 01, 2004.
How many employees does Immatics have?
As of Dec 31, 2024, the latest employee count at Immatics is 423.
What is the annual revenue of Immatics?
Annual revenue of Immatics is $168.57M as on Dec 31, 2024.
What does Immatics do?
Founded in 2000 and based in Tubingen, Germany, the company operates in the biotechnology sector, focusing on cancer immunotherapies. A proprietary platform called XPRESIDENT is utilized to identify and validate cancer-specific antigens. Adoptive cell therapies and bispecific T-cell receptors are subsequently developed for cancer treatment. The IMA101 product is generated through the ACTolog approach, employing T-cells from peripheral blood with targeted selectivity.
Who are the top competitors of Immatics?
Immatics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Immatics offer?
Immatics offers Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT.
Is Immatics publicly traded?
Yes, Immatics is publicly traded on NASDAQ under the ticker symbol IMTX.
Who are Immatics's investors?
Immatics has 16 investors. Key investors include 3i Group, European Union, KfW, Bristol-Myers Squibb, and DH Capital.
What is Immatics's ticker symbol?
The ticker symbol of Immatics is IMTX on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.